Results for "Specialty Pharmaceutical Distribution Facts, Figures, and Trends"
HDA Statement on “Most-Favored-Nation” Executive Order
HDA released a statement in response to President Donald J. Trump’s Executive Order establishing a “Most-Favored-Nation” (MFN) pricing policy for pharmaceuticals.
The Rx for Drug Shortages? A Better Understanding of the Supply Chain and Collaborative Solutions
As patients face challenges related to drug shortages, policymakers, regulators and healthcare supply chain leaders are engaged in ongoing discussions about mitigating threats and impact. In this piece, HDA's President and Chief Executive Officer Chip Davis explores some causes and solutions for drug shortages, and how distributors support a resilient supply chain through collaborative efforts and logistics expertise.
Faces of the Supply Chain: Distribution Sector Career Pathways
As some of the best minds in distribution convened for the 2024 Distribution Management Conference, HDA spoke with professionals at all stages of their careers to explore paths that led to them to rewarding work. Their insights are featured in the latest installment of the Faces of the Supply Chain video series. In part two of our two-part series, we share some of the valuable perspectives on careers in distribution highlighted during these conversations.
HDA Statement on FDA Distributor Licensure Proposed Rule
The Healthcare Distribution Alliance (HDA) released the following statement from President and CEO Chester “Chip” Davis Jr., regarding FDA’s proposed rule, issued as required by the Drug Supply Chain Security Act (DSCSA), entitled “National Standards for Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers.”